CJC-1295 + Ipamorelin: A Research Reference Overview

What is CJC-1295 + Ipamorelin?

CJC-1295 and Ipamorelin are distinct synthetic peptides that appear together in the research literature because they act on different points of the growth-hormone (GH) signaling pathway. CJC-1295 is described as a long-acting analog of growth-hormone-releasing hormone (GHRH), specifically a modified hGRF(1-29) sequence. In the originating study, researchers characterized it as a bioconjugate able to bind plasma albumin, which was associated with an extended plasma presence in rat models (Teichman/Jette et al., 2005). Ipamorelin is a pentapeptide first reported in 1998 as a growth-hormone secretagogue that acts as an agonist at the GH secretagogue (ghrelin) receptor (Raun et al., 1998).

The two are studied as a combination because GHRH analogs and ghrelin-receptor agonists engage separate receptor systems on pituitary somatotrophs. This combination is offered as a reference-grade research material only and is not intended for human or animal administration.

Studied mechanisms

In the published literature, CJC-1295 has been examined as a GHRH-receptor agonist. The foundational rat study identified it as a long-lasting GRF analog that activated the GRF receptor on the anterior pituitary, with detectable plasma presence beyond 72 hours owing to its albumin-binding (drug affinity complex) design (Teichman et al., 2005, PMID 15817669).

Ipamorelin has been characterized as acting through a GHRP-like (ghrelin) receptor pathway distinct from the GHRH receptor. A frequently cited feature in the literature is its reported selectivity: in the original 1998 characterization, researchers observed GH-releasing potency comparable to GHRP-6 but, notably, without the significant ACTH or cortisol elevation seen with other secretagogues, even at doses far above the GH-effective level (Raun et al., 1998, PMID 9849822). Because the two peptides are studied as engaging separate receptor systems, researchers have examined them as a model of converging input onto the somatotropic axis.

Research models and findings (hedged)

Reported findings for these peptides derive from animal and in-vitro systems and should be read only in that context. For CJC-1295, a 2006 study reported that once-daily administration normalized growth metrics in a GHRH-knockout mouse model, and was associated with increased pituitary GH mRNA in that system (PMID 16822960). Earlier work associated CJC-1295 with sustained activation of the GH/IGF-1 axis in preclinical evaluation.

For Ipamorelin, researchers have examined somatotroph responsiveness following chronic administration in young female rats using in-vitro pituitary preparations (PMID 12168778), and have separately characterized its pharmacokinetic behavior, including nasal absorption and clearance relative to other secretagogues (PMID 9879640). These observations are confined to laboratory models and are not evidence of any effect in humans.

Research applications and context

Within the secretagogue literature, CJC-1295 and Ipamorelin are most often referenced in studies of the GHRH-receptor and ghrelin-receptor signaling systems and their convergence on pituitary GH regulation. Researchers have used such compounds as pharmacological probes to dissect receptor-specific contributions to GH pulsatility in animal and cell-culture systems.

VANTA supplies these materials only as reference standards and research reagents for qualified laboratory investigators. Nothing on this page should be interpreted as guidance for use in humans, as a description of any health benefit, or as a substitute for the primary literature. Investigators should consult the cited studies directly and follow all applicable institutional and regulatory requirements for handling research chemicals.

How VANTA verifies it

Every VANTA research peptide is verified before it reaches a researcher. Identity is confirmed by mass spectrometry, where the measured molecular mass is checked against the theoretical mass for each peptide sequence in the combination. Purity is assessed by reversed-phase high-performance liquid chromatography (HPLC), which resolves the target peptide from process-related impurities and quantifies the main-peak percentage.

Each lot ships with a per-batch Certificate of Analysis (COA) documenting the HPLC purity result, the mass-spec identity confirmation, and lot-specific details. This per-batch documentation lets a laboratory confirm what was received against an independent analytical record, supporting reproducibility and traceability in research-use-only workflows.

References

1. 1.Jetté et al. (2005) - hGRF(1-29)-albumin bioconjugates activate the GRF receptor in rats; identification of CJC-1295 as a long-lasting GRF analog (Endocrinology)
2. 2.Raun et al. (1998) - Ipamorelin, the first selective growth hormone secretagogue (Eur J Endocrinol)
3. 3.Alba et al. (2006) - Once-daily CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH-knockout mouse (Am J Physiol Endocrinol Metab)
4. 4.Jiménez-Reina et al. (2002) - Chronic Ipamorelin treatment in young female rats: somatotroph response in vitro (Histol Histopathol)
5. 5.Johansen et al. (1998) - Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues, emphasis on nasal absorption (Xenobiotica)